COMMUNIQUÉS West-GlobeNewswire

Invuity to Present at Piper Jaffray Healthcare Conference

21/11/2017 - 14:00

SAN FRANCISCO, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ: IVTY ), a leading medical technology company focused on minimal access surgery, today announced that company management is scheduled to present at [...]

TESARO Secures $500 Million Non-Dilutive Term Loan Financing

21/11/2017 - 14:00

WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO ), an oncology focused biopharmaceutical company, announced today that it has entered into a definitive term loan agreement with BIOPHARMA [...]

aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference

21/11/2017 - 14:00

SAN DIEGO, Nov. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering [...]

Ovid Therapeutics Announces Five Poster Presentations on TAK-935/OV935 at the American Epilepsy Society 71st Annual Meeting

21/11/2017 - 14:00

NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines for patients with rare neurological diseases, today announced that it [...]

New Data from Zogenix’s Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at 71st American Epilepsy Society Annual Meeting

21/11/2017 - 14:00

Updated Results of Phase 2 Study of ZX008 in Lennox Gastaut Syndrome to be Presented Data Demonstrating Disease Burden and Negative Impact on Quality of Life of Patients and Families Will Also be Presented EMERYVILLE, [...]

VBL Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference

21/11/2017 - 14:00

TEL AVIV, Israel, Nov. 21, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for [...]

Aclaris Therapeutics Presents New Data at American College of Rheumatology Annual Meeting For ATI-450, a MK2 pathway Inhibitor

21/11/2017 - 14:00

MALVERN, Pa., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS ), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and [...]

Uptick Network “Stock Day” Interviews New HealthWarehouse CEO Joseph Peters on Company Success in 2017

21/11/2017 - 14:00

Florence, KY, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Uptick Network “Stock Day” interviews Joseph Peters, CEO of HealthWarehouse.com Inc. ( OTC:HEWA , the “Company” or “HealthWarehouse”) on Company success in 2017 with host [...]

Cytokinetics Announces Negative Results From VITALITY-ALS

21/11/2017 - 13:30

Phase 3 Clinical Trial of Tirasemtiv in Patients with ALS Did Not Meet Primary or Secondary Endpoints Results to be Presented December 8 th at 28th International Symposium on ALS/MND Conference Call Today at 8:30 a.m. [...]

Immunovaccine and Leidos Expand Collaboration to Develop Malaria Vaccines Formulated in DepoVax™

21/11/2017 - 13:05

HALIFAX, Nova Scotia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immunotherapy and vaccine company, today announced that it is expanding its collaboration with [...]

GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Epidiolex® (cannabidiol) Data and Educational Programs at the American Epilepsy Society Annual Meeting

21/11/2017 - 13:00

LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel [...]

Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference

21/11/2017 - 13:00

WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH ), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today [...]

Kamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies Infection

21/11/2017 - 13:00

Three-Year Agreement Expected to Provide Revenues of Approximately $13 Million to Company Kamada’s Rabies Immune Globulin Recently Received FDA Approval REHOVOT, Israel, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. ( [...]

Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor

21/11/2017 - 13:00

Anavex’ Sigma-1 Receptor Agonists Protect Mitochondrial Function from Amyloid Toxicity and Absence of Sigma-1 Receptor Function Exacerbates Amyloid Toxicity NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- New data published [...]

ProQR to Present at the Annual Piper Jaffray Healthcare Conference

21/11/2017 - 13:00

LEIDEN, the Netherlands, Nov. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq: PRQR ), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe [...]

Emerald Health Therapeutics Completes Investment in Licensed Dealer Northern Vine

21/11/2017 - 13:00

VICTORIA, British Columbia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (“Emerald”) (TSX-V: EMH ) (OTCQX:EMHTF) announced today that it has completed its previously announced investment of $2.5 [...]

Abattis Announces Completion of Investment by Emerald Health Therapeutics in Northern Vine

21/11/2017 - 13:00

VANCOUVER, British Columbia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce the closing of its previously announced agreement with [...]

Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma

21/11/2017 - 12:58

Company Announcement Application to broaden label for daratumumab in front line multiple myeloma submitted to EMA Submission based on data from Phase III ALCYONE study Genmab to receive USD 3 million in milestone [...]

Transactions in relation to share buyback program

21/11/2017 - 12:15

Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]